ClinicalTrials.gov
public full text
Public Domain
Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome
Use the Intermountain real-world MAb-treatment registry and control group to prospectively evaluate PACS symptoms at least 60 days after initial COVID-19 diagnosis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age#652989
- A Study of CIN-107 in Adults With Primary Aldosteronism#1104274
- Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy#254049
- Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID#1151773
- Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously#5161
Record · ID 886262
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive